Your browser doesn't support javascript.
loading
Hemorragia alveolar secundaria a lupus eritematoso generalizado, tratada con factor VII recombinante activado: reporte de un caso y revisión de la literatura / Alveolar hemorrhage secondary to generalized systemic lupus erithematosus treated with recombinant activated factor VII: case report and literature review
Carrillo-Esper, Raúl; Elizondo-Argueta, Sandra; Sánchez-Zúñiga, Martín de Jesús; Carrillo-Córdova, Jorge Raúl.
Affiliation
  • Carrillo-Esper, Raúl; Hospital Angeles Lomas. Unidad de Terapia Intensiva. México D.F. MX
  • Elizondo-Argueta, Sandra; Universidad Nacional Autónoma de México. Facultad de Medicina. México D.F. MX
  • Sánchez-Zúñiga, Martín de Jesús; Hospital Sante Fé. Servicio de Terapia Intensiva. México D.F. MX
  • Carrillo-Córdova, Jorge Raúl; Universidad Nacional Autónoma de México. Facultad de Medicina. México D.F. MX
Gac. méd. Méx ; 143(1): 83-86, ene.-feb. 2007. ilus, tab
Article in Spanish | LILACS | ID: lil-568888
Responsible library: BR1.1
RESUMEN
La hemorragia alveolar es una complicación grave del lupus eritematoso generalizado (LEG), asociada a una elevada mortalidad. El tratamiento de esta complicación se apoya en el uso de corticoesteroides, ciclofosfamida; en algunas series, se recomienda el uso de metrotexate, azatioprina y plasmaféresis. En la literatura se encuentra un solo caso informado en el cual se informa el empleo del factor VII recombinante activado (FVIIra) como opción terapéutica para la hemorragia secundaria a alveolitos, refractaria al tratamiento habitual. Presentamos el caso de una paciente que desarrolló hemorragia alveolar grave con diagnóstico previo de LEG y que se manejó con FVIIra.
ABSTRACT
Alveolar hemorrhage is a severe complication of systemic lupus erithematosus (SLe) associated with high mortality. Treatment includes administration of steroids and cyclophosphamide. Additionally, some reports have recommended the use of plasmapheresis, azathioprine and methotrexate. There is a single case reported in the literature in which recombinant activatedfactor VII (rFVIIa) was used to control severe hemorrhage secondary to alveolitis unresponsive to standard treatment. We report the case of a patient with SLE who developed severe alveolar hemorrhage unresponsive to standard measures, but who was successfully treated with rFVIIa.
Subject(s)

Full text: Available Collection: International databases Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Immune Disorders / Musculoskeletal Diseases and Rheumatic Disorders Database: LILACS Main subject: Recombinant Proteins / Factor VIIa / Hemorrhage / Lupus Erythematosus, Systemic Limits: Adolescent / Female / Humans Language: Spanish Journal: Gac. méd. Méx Journal subject: Medicine Year: 2007 Document type: Article Affiliation country: Mexico Institution/Affiliation country: Hospital Angeles Lomas/MX / Hospital Sante Fé/MX / Universidad Nacional Autónoma de México/MX
Full text: Available Collection: International databases Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Immune Disorders / Musculoskeletal Diseases and Rheumatic Disorders Database: LILACS Main subject: Recombinant Proteins / Factor VIIa / Hemorrhage / Lupus Erythematosus, Systemic Limits: Adolescent / Female / Humans Language: Spanish Journal: Gac. méd. Méx Journal subject: Medicine Year: 2007 Document type: Article Affiliation country: Mexico Institution/Affiliation country: Hospital Angeles Lomas/MX / Hospital Sante Fé/MX / Universidad Nacional Autónoma de México/MX
...